title: Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management.
abstract: According to the World Health Organization classification of pituitary tumors, only tumors with systemic metastasis must be considered as carcinomas. Invasive tumors with multiple recurrences are only classified as aggressive tumors or "atypical adenomas". To illustrate the problems encountered in the pathological diagnosis of pituitary carcinoma and in patient management, we present two male patients operated on for an aggressive prolactin pituitary adenoma with and without metastasis. In case 1, 5 surgeries, 3 irradiations, increased doses of dopamine agonists, and trials of temozolomide and carboplatine-VP16 failed to control tumor progression and the appearance of metastases which lead to death 16 years after onset. In case 2, based on the initial diagnosis of an aggressive-invasive adenoma that was resistant to dopamine agonists, gamma-Knife irradiation was initially performed on the intra-cavernous remnant. Eight years after onset, the remnant remained stabilized and the plasma PRL normalized under dopamine agonist. From these 2 cases alongside other cases found in the literature, we propose that the association of certain clinical signs (male sex, dopamine-resistant hyperprolactinemia), radiological signs (invasive macro or giant tumor on MRI) and histological signs (angiogenesis, Ki-67 > 3%, p53 positive, mitoses >2 per high power field, vascular invasion, up-regulation of genes related to invasion and proliferation, and allelic loss of chromosome 11) might suggest aggressiveness and be suspicious of malignancy before the appearance of metastasis. The early detection of an aggressive phenotype of a prolactin pituitary tumor should permit the earlier establishment of the optimum therapeutic strategy associating surgery and radiotherapy to delay or inhibit metastasis.
authors.affiliation: Service de Neurochirurgie, CHU de Tours, Tours, France, ilyess.zemmoura@univ-tours.fr.
authors.forename: Ilyess
authors.initials: I
authors.lastname: Zemmoura
authors.forename: Anne
authors.initials: A
authors.lastname: Wierinckx
authors.forename: Alexandre
authors.initials: A
authors.lastname: Vasiljevic
authors.forename: Michel
authors.initials: M
authors.lastname: Jan
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Trouillas
authors.forename: Patrick
authors.initials: P
authors.lastname: François
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D011388:Prolactin / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D011388:Prolactin